[6-K] EDAP TMS SA Current Report (Foreign Issuer)

Rhea-AI Filing Summary

EDAP TMS (EDAP) highlights its position as a global leader in robotic high-intensity focused ultrasound (HIFU) for prostate cancer, BPH and endometriosis, supported by growing clinical use and reimbursement. The company reports revenue of $16.1 million for the three months ended September 30, 2025, up from $14.4 million, with gross margin improving to 43.0% from 39.4%. HIFU revenue rose to $7.7 million from $4.9 million, while distribution and ESWL lines declined.

EDAP remains loss-making, with operating loss of $5.7 million and net loss of $5.8 million for the quarter, slightly better than a year earlier. For the nine-month period, revenue was $48.8 million with net loss of $19.8 million. Cash and cash equivalents were $12.4 million as of September 30, 2025. The company reports 76 Focal One systems installed in the U.S. and emphasizes expanding indications, strong clinical evidence, and favorable Medicare reimbursement as foundations for future growth.

Insights

Medical device equity analyst

EDAP shows strong HIFU growth and better margins but continues to post losses with lower cash.

EDAP TMS positions its Focal One robotic HIFU as a leading focal therapy platform in prostate cancer, with expansion into BPH and endometriosis. The business mix is shifting toward HIFU, which reached quarterly revenue of $7.7 million versus $4.9 million a year earlier, while distribution and ESWL activities declined. This mix shift supports a higher gross margin of 43.0%, up from 39.4%.

Despite top-line growth to $16.1 million in Q3 2025 and improved operating loss of $5.7 million, the company remains unprofitable, with nine-month net loss of $19.8 million. Cash and cash equivalents fell to $12.4 million as of September 30, 2025, while shareholders’ equity declined to $27.4 million, indicating ongoing funding needs if losses persist.

The installed base reached 76 Focal One systems in the U.S. as of September 30, 2025, with reported compounded annual growth in procedures and installations, and the platform adopted by many top-ranked urology centers. Future performance will depend on continued procedure growth on this installed base, execution in new indications such as BPH and endometriosis, and the company’s ability to manage cash while it scales.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

November 18, 2025

Commission File Number: 0-29374

EDAP TMS S.A.
Parc Activite La Poudrette Lamartine
4/6 Rue du Dauphine
69120 Vaulx-en-Velin - France

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ x]      Form 40-F [  ]

SIGNATURES

Pursuant to the requirements of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: November 18, 2025

EDAP TMS S.A.

/s/ KEN MOBECK
KEN MOBECK
CHIEF FINANCIAL OFFICER

The Global Leader in Therapeutic Ultrasound 1

Statements & Disclaimer F O R W A R D - L O O K I N G 2

Company Overview 3

Strategic Company Focus 4 Global Leader in Therapeutic Ultrasound for the Treatment of Cancer and Benign Disease

Investment Thesis: Strong Growth Opportunity 5 x Large and Growing Market Opportunity: Urology and Prostate Cancer x Solves an Important Unmet Clinical Need in Cancer x Proven Compelling Clinical Evidence x Increasing Patient and Physician Demand x Strong Hospital and Physician Reimbursement x Leverages Current Advancements in Imaging, AI, and Robotics x Growing Worldwide Install Base x Ideally Positioned for Expanded Indications (BPH, Endometriosis, Other)

350+ Focal One Robotic H FU Clinical Sites

Large and Growing Market Opportunity In Urology and Prostate Cancer 7

3.3 Million American Men Living with Prostate Cancer in the U.S. (1) 313,780 New Cases Diagnosed in the U.S. (1) 35,770 U.S. Deaths from Prostate Cancer (1) U . S . P R O S T A T E C A N C E R M A R K E T Prostate Cancer is the Most Common Cancer Amongst Men In the U.S. Prostate (1) 2025 estimates from the American Cancer Society ( www.cancer.org ) 8 Lung & Bronchus Colorectum Skin Urinary Bladder New Cases Deaths

Prostate Cancer Market Opportunity Number of New Prostate Cancer Cases Region 473,011 Europe 386,424 Asia 255,782 North America 225,985 Latin America 103,050 Africa 23,602 Oceania 1,467,854 Total L A R G E G L O B A L M A R K E T 1.5 Million New Prostate Cancer Cases Per Year 9 Data Source: Cases refers to Diagnosed Cases per year From World Health Organization – Globocan 2022

Focal One Answers an Unmet Need for a Large Underserved Patient Population P R O S TA TE C A N C E R Focal One HIFU Focal One HIFU 10 First - Line Treatment Progression from Active Surveillance Salvage Treatment

11 470,000 165,000 11 Based on 2023 Internal Company Estimates 130,000 100,000 75,000 Europe Asia North America South America Focal One HIFU Prostate Cancer Annual Procedure Opportunity F O C A L O N E R O B O T I C H I F U Global Addressable Market

12 D R I V I N G A P A R A D I G M S HI F T I N P R O S T A T E C A N C E R Focal Therapy | The New Emerging Market (1) As of 2013. Chen et al. National trends in the management of localized prostate cancer: A population - based analysis 2004 - 2013. Prostate. (2) Internal market estimate Active Surveillance Radical Prostatectomy (Surgery) Radiation Therapy Active Surveillance Radical Prostatectomy (Surgery) Radiation Therapy Focal Therapy (HIFU) Traditional Market (1) Emerging Market (2) Future Market (2) Active Surveillance Radical Prostatectomy (Surgery) Radiation Therapy Focal Therapy (HIFU)

13 CANCER CONTROL PATIENT BURDEN Treatment Comparison Focal One HIFU Provides the Optimal Organ - Preserving Patient Treatment ORGAN - PRESERVING STRATEGY WHOLE - GLAND RADICAL TREATMENT STRATEGY QUALITY OF LIFE FUNCTIONAL OUTCOMES 96% (3) Continence Preservation 82% (3) Erectile Function Preservation - Ejaculation Preservation Low Risk of Complications - Typical Complications - Treatment Process Active Surveillance N/A 10 - year Cancer Specific Survival (*) Hospital stay duration for radical prostatectomy may vary (1) Yeh, HT et al. 10 - year oncological outcomes of EBRT versus HIFU for stage II prostate cancer: a multicenter Chang Gung research database (CGRD) study wi th inverse - probability - of - treatment weighting (IPTW) analysis. Int Urol Nephrol (2025). (2) Stensland KD et al. National Long - term Survival Estimates After Radical Prostatectomy for Prostate Cancer. Urology. 2024 Feb;184:135 - 141. (3) Donovan JL, et al. Patient - Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. N Engl J Med. 2016 Oct 13. (4) Sullivan JF et al. Ejaculation profiles of men following radiation therapy for prostate cancer. J Sex Med. 2013 May;10(5):1410 - 6. (5) Arnouil, N., et al. "Traitement focal par HIFU versus prostatectomie radicale robot - assistée pour cancer de la prostate localisé: résultats carcinol ogiques et fonctionnels à 1 an." Progrès en Urologie 28.12 (2018): 603 - 610. (6) von Hardenberg J et al. Prostate cancer treatment by the latest focal HIFU device with MRI/TRUS - fusion control biopsies: A prospective evaluation. Urologic Oncology: Seminars and Original Investigations, Volume 36, Issue 9, 2018, Pages 401.e1 - 401.e9 75% (3) 96% (3) 98% (5) 69% (3) 49% (3) 93% (5) 0% 28% (4) 96% (6) High Medium Low Blood Loss and Other Surgical Complications Radiation Toxicity, Risk of Secondary Cancers - 1 Session 1 - Day Hospital Stay (*) 45 Sessions 45 Visits 1 Session, Same Day Outpatient Procedure Radiation Surgery Radical Prostatectomy Focal One ® Robotic HIFU 99% (2) 91% (1) 95% (1)

D R I V I N G A P A R A D I G M S HI F T I N P R O S T A T E C A N C E R HIFU | The Fastest Growing Treatment Option Based on Medicare Claims reported by CMS on HOPPS Proposed Rule for FY24, FY25 and FY26 14 HIFU Cryo Brachytherapy Radical Prostatectomy

Strong Supporting Clinical Evidence 15

16 Proven Clinical Evidence Supporting Focal One Robotic HIFU 3. Preserve Sexual Function 2. Maintain Urinary Control 1. Cancer Control 1000+ Peer - Reviewed Publications Supporting HIFU in the Treatment of Prostate Cancer (1) Optimizing Trifecta Outcomes for Prostate Cancer (1) PubMed Database search of “HIFU Prostate Cancer” Functional Outcomes 16

17 HIFI - Prospective Multicentric Comparative Study Focal One HIFU vs Radical Prostatectomy Prospective, Comparative, Multicentric , non - inferiority clinical trial comparing HIFU to Radical Prostatectomy (RP) 3,328 patients treated (1,967 HIFU - 1,361 RP) across 46 centers 90% of HIFU patients treated with Focal One Comparable Cancer Control (Primary Endpoint): 90% STFS for HIFU vs 86% for RP; p = 0.008 Superior functional outcomes for HIFU (Secondary Endpoint): • Urinary Continence significantly better after HIFU • Significantly lower stress incontinence after HIFU • Erectile Function less impaired Published in European Urology – December 2024 Ploussard et al. “Whole - gland or Subtotal High - intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial.” European urology vol. 87,5 (2025): 526 - 533. doi:10.1016/j.eururo.2 024.11.006

18 18 HIFI Study Demonstrates Optimal Trifecta Outcomes 1. Cancer Control 3. Preserve Sexual Function 2. Maintain Urinary Control Δ 11% Urinary Continence Pad - Free Continence at 12 months HIFU Provides Superior Functional Outcomes Δ 6 HIFU SURGERY Erectile Function Decrease from baseline at 12 months HIFU SURGERY Comparable Oncologic Outcomes Patients Free from Salvage Treatment at 30 months HIFU RADICAL PROSTATECTOMY 90% 86% Ploussard et al. “Whole - gland or Subtotal High - intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial.” European urology vol. 87,5 (2025): 526 - 533. doi:10.1016/j.eururo.2 024.11.006

19 FARP - Randomized Controlled Trial Focal Ablation vs Radical Prostatectomy Randomized Controlled, Non - inferiority Clinical Trial comparing Focal Ablation (FA) to Robot - Assisted Radical Prostatectomy (RP) Equivalent Oncologic Control at 3 years (93.5% TFF vs 91.5%) Superior Functional Outcomes after Focal Ablation 213 Patients included in the Clinical Trial 25% of Patients refused radical surgery after randomized to RP and opted for FA 80+% of Focal Ablation patients treated with Focal One ® Baco et al. Final, three - year oncological results of a randomized clinical trial FARP comparing Focal Ablation and Radical Prostatectomy in patients with unilateral clinically - significant prostate cancer. Journal of Urology [Internet]. 2025 May 1;213 (5S):e714. Baco et al. Focal Ablation Versus Radical Prostatectomy for Intermediate - Risk Prostate Cancer: Interim Analysis of a Randomized Controlled Trial. The Journal of Urology. Vol. 206, No. 3 S, Supplement, Sunday, September 12 , 2021 Final Results Presented at AUA 2025 0% 20% 40% 60% 80% 100% Oncologic Control (ITT Treatment Failure Free) Continence (Pad - free) Erectile Function Preservation Surgery Ultrasound Focal Ablation Surgery Ultrasound Focal Ablation Surgery Ultrasound Focal Ablation O P T I M A L T R I F E C T A O U T C O M E S

20 HIFU Demonstrates Equivalent 10 - year Survival to Radiation Therapy 10 - year Oncological Outcomes of HIFU vs EBRT (1) • Lower Mortality at 10 years post HIFU (9.2%) compared to EBRT (16.7%) • Lower Cancer - Specific Mortality after HIFU (5.4%) compared to EBRT (9.2%) Yeh, HT., Liu, YY., Chang, Y.L. et al. 10 - year oncological outcomes of EBRT versus HIFU for stage II prostate cancer: a multicenter Chang G ung research database (CGRD) study with inverse - probability - of - treatment weighting (IPTW) analysis. Int Urol Nephrol (2025 ). https://doi.org/10.1007/s112 55 - 025 - 04805 - 7 Radiation HIFU HIFU Radiation

21 Strong Hospital and Physician Reimbursement

22 Environment for Growth S T R O N G R E I M B U R SE M E N T Creates Favorable 1. APC Level 6 Under CMS for CY23 and CY24 (1,3) 2. 90% Increase in Reimbursement in 2023 (1,2) 3. APC Level 6 Maintained by CMS in 2025 (3) (1) CMS Hospital Outpatient Prospective Payment System - 2023 Final rule (2) CMS Hospital Outpatient Prospective Payment System - 2022 Final rule (3) CMS Hospital Outpatient Prospective Payment System – 2025 Final rule

23 Hospital Outpatient Medicare Payment (Laparoscopic Prostatectomy with or without Robotic Assistance and/or nerve - sparing) ( 1) Medicare Payment (National Average. From on CMS Hospital Outpatient Prospective Payment System – 2025 Final rule 2025 Site of Service CPT ® Code Procedure $5,084 (1) Standard OR 55875 Prostate Brachytherapy $9,247 (1) Standard OR 55873 Cryo Ablation $12,992 (1) Specialized MRI Suite C9734 / 55882 MRI Transurethral Ultrasound Ablation $9,247 (1) Standard OR 55880 HIFU $10,411 (1) Standard OR 55866 Laparoscopic Prostatectomy +5.4%

24 Favorable Physician Payment (Laparoscopic Prostatectomy with or without Robotic Assistance and/or nerve - sparing) (1) CMS Physician Fee Schedule – CY 2024 Final rule (2) CMS Physician Fee Schedule – CY 2 025 Final rule Physician Payment (Medicare - 2025) Work RVU (2025) (2) CPT ® Code Procedure $763 13.46 55875 Prostate Brachytherapy $744 13.60 55873 Cryo $579 11.50 55882 MRI Transurethral Ultrasound Ablation $951 17.73 55880 HIFU $1,157 22.46 55866 Laparoscopic Prostatectomy

Focal One ® Best - in - Class Technology 25

Precise Robotic Delivered Ablation 26 T HE L E A D I N G F O C A L T HE R A P Y T E C H N O L O G Y Targeting and Imaging Image Guided Treatment Planning

Robotics HIFU Advanced Imaging Focal One ® Core Technologies Artificial Intelligence (AI) Remote Connectivity 27

28 Integrated Workstation Compatible With Standard OR Beds MRI, PSMA PET Unfold AI* , OnQ Prostate* Koelis* and DynaCAD* 3D Biopsy HIFUsion ® Image - Guided Treatment Planning Dynamic Focusing Probe Precise Robotic Positioning Multi - Axis Sub - millimeter Robotic Movements Auto - Adjusting Pinpoint Delivery of HIFU Energy The Most Advanced Robotic HIFU Platform Controlled by Urologists • Expanded HIFUsion ® Capabilities • Streamlined Treatment Workflows • Embedded Video Content Library • Treatment Streaming and Recording* • Remote Proctoring & Telecollaboration* • Endometriosis Treatment Ready* * Not available in all markets. May require additional purchase

29 World’s First Focal One Robotic HIFU Transcontinental Telecollaboration Cleveland Clinic Cleveland, Ohio Cleveland Clinic Abu Dhabi Cleveland, Ohio Abu Dhabi 7,000 Miles 29

BPH & Endometriosis Large Market Opportunities For Expansion 30

31 HIFU Unlocks a Large Market Opportunity (1) Newly Diagnosed Cases per year From World Health Organization – Globocan 2022 (2 ) From WHO and Habib N et al. Bowel Endometriosis: Current Perspectives on Diagnosis and Treatment. Int J Womens Health. 2020 (3 ) Xu et al.. Global, Regional, and National Incidence and Year Lived with Disability for Benign Prostatic Hyperplasia from 1990 to 2019. Am J Mens Health. 2021 (4) Based on UN Population Division and Goehring et al. Epidemiology of benign breast disease, with special attention to histologic types. Epidemiol Rev. 1997 (5 ) Based on UN Population Division and Bomeli et al. Evaluation of a thyroid nodule. Otolaryngol Clin North Am. 2010 20.5 M (2) Rectal Endometriosis 1.5 M Prostate Cancer (1) 11.3 M (3) BPH (Benign Prostatic Hyperplasia) 510,992 (1) Pancreatic Cancer 866,136 (1) Liver Cancer 51.4 M (5) Thyroid Nodules 2.3 M (1) Breast Cancer 8.3 M (4) Breast Fibroadenoma

94 Million Global cases of BPH in 2019 (1) 15 Million U.S. men are affected by BPH/LUTS (2) 600,000 U.S. men aged 65+ newly diagnosed annually (3) Leveraging Expertise in Robotic HIFU and Prostate for BPH 12.2 Million men actively managed for BPH/LUTS: • 55% under Drug Management (4) • 35% under Watchful Waiting (4) • 300,000+ Active Surgical Treatments (5) Focal One Robotic HIFU technology has the potential to provide a non - invasive option that can safely treat BPH - related symptoms while avoiding the side effects of standard surgical treatments. 10,000s PCa treatments constitute a robust foundation to build upon for a BPH strategy (1) Fentahun et al. The Lancet Healthy Longevity. 2022 (2) Egan K B. Urologic Clinics of North America. 2016 (3) Urologic Diseases in America. 2024. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2024 (4) Vuichoud et al. Can J Urol. 2015 (5) Internal market estimate B E N I G N P R O S T A T I C H Y P E R P L A S I A ( B P H ) M A R K E T 32

B P H : F O C A L O N E C L I N I C A L S T U D Y P R O G R E SS Building High - Level Evidence in the Treatment of Benign Prostate Hyperplasia Feasibility Study Completed Phase I - II Study Recruiting • Monocentric Feasibility Study (9 patients) • Confirmed Safety and potential for improvement of BPH - related symptoms • First Patients Treated • Phase I: Three - center study HIFU dose escalation • Phase II: Multi - center Study Safety and Efficacy of Final HIFU Parameters as defined in Phase 1 ض ض ض 33 U.S. Study Under IRB Review • Protocol based on previous study findings

6.5 Million US Women Have Endometriosis (1) 1.3 Million 20% of Cases are Deep Infiltrating Endometriosis (DIE) in the U.S. (2) 11% of U.S. Women are Affected by Endometriosis (2) Leveraging Expertise in Robotic HIFU For Endometriosis Common symptoms of Rectal Endometriosis may include various conditions (acute pelvic pain, constipation, diarrhea, rectal bleeding), all of which negatively impact quality of life and ability to become pregnant. Current treatment options are lacking and limited to hormonal and/or surgical management Focal One has the potential of offering a non - invasive option with the ability of Reducing Symptoms and Improving Quality of Life (1) Office of Women’s Health ( www.womenshealth.gov) (2 ) D'Alterio MN et al. Management Challenges of Deep Infiltrating Endometriosis. Int J Fertil Steril. 2021 Apr;15 (2):88 - 94. doi: 10.22074 /IJFS.202 0.134689. Epub 2021 Mar 11. PMID: 33687160; PMCID: PMC8052801 U . S . 34 E N D O M E T R I O S I S M A R K E T

35 E N DO M E TR I O S I S : F O C A L O N E C L I N I C A L S T U D Y P R O G R E SS Building High - Level Evidence in the Treatment of Deep Infiltrating Rectal Endometriosis Phase I Study Completed Phase II Study Completed • Feasibility (20 patients) • Published in the Journal of Ultrasound in Obstetrics and Gynecology in 2020 • Multicenter Safety and Efficacy Study ( 60 patients) • Completed in March 2022 • Published in Journal of Human Reproduction in 2024 • Multicenter Double - Blind Randomized Controlled Trial (RCT) • Enrollment completed (60 patients) • Follow - up of all patients in progress • 85% of Sham Group patients elected and received HIFU Treatment ض ض ض • Focal One received CE mark certification for the treatment of posterior deep endometriosis infiltrating the rectum Phase III Study CE Mark Completed Enrollment March 25, 2025 ض

Growing Global Install Base 36

F O C A L O N E A DO P T I O N A C C E L E R A T I N G At Major Hospitals 76 Focal One Systems in U.S. as of September 30, 2025 (39 Academic – 37 Community) 37

Focal One U.S. Momentum 2021 - 2024 (Compounded Annual Growth Rates) Focal One Procedures CAGR 38 Focal One Installations CAGR 67% 51%

Strong Adoption by the Highest Ranked Prostate Cancer Hospitals in the US F O C A L O N E I S T HE L E A D I N G F O C A L T H E R A P Y T E C H N O L O G Y 70% 7 Out of 10 Best Hospitals for Urology National Comprehensive Cancer Network® 52% 17 Out of 33 NCCN Member Institutions 60% 21 Out of 35 SUO Approved Programs 39

Key Financial Data 40

T HR E E M O N T HS E N D E D S E P T E M B E R 3 0 T H 2025 2024 (in $Million USD except per share data) 16.1 14.4 Revenue 6.9 5.7 Gross Profit 43.0% 39.4% Gross Margin (5.7) (6.4) Operating Profit (Loss) (5.8) (7.0) Net Income (Loss) (0.16) (0.19) Earnings (Loss) Per Share HIFU $4.9M HIFU $7.7M +57% 3 months 2024 3 months 2025 $ 1 4 . 4 M Distribution $6.3M - 14% Distribution $7.3M ESWL $2.1M - 4% ESWL $2.2M NOTE: Translated for convenience of the reader to U.S. dollars at the 2025 average three months’ exchange rate of 1 Euro = 1.1620 USD, and 2024 average three months’ exchange rate of 1 Euro = 1.1010 USD 41 $ 1 6 . 1 M Financial Highlights as of September 30, 2025

N I N E M O N T HS E N D E D S E P T E M B E R 3 0 T H 2025 2024 (in $Million USD except per share data) 48.8 47.6 Revenue 20.7 19.0 Gross Profit 42.5% 39.9% Gross Margin (18.7) (18.2) Operating Profit (Loss) (19.8) (18.5) Net Income (Loss) (0.53) (0.50) Earnings (Loss) Per Share HIFU $16.3M HIFU $23.9M +46% Distribution $19.1M - 21% Distribution $24.1M ESWL $5.7M - 20% ESWL $7.1M 9 months 2024 9 months 2025 $ 4 7 . 6 M NOTE: Translated for convenience of the reader to U.S. dollars at the 2025 average nine months’ exchange rate of 1 Euro = 1.1213 USD, and 2024 average nine months’ exchange rate of 1 Euro = 1.0858 USD 42 $ 4 8 . 8 M Financial Highlights as of September 30, 2025

43 Balance Sheet Highlights as of September 30, 2025 Balance Sheet As Of: September 30, 2024 September 30, 2025 (in $Million USD) 28.4 12.4 Cash and Cash Equivalents 42.9 39.6 Other Current Assets 16.8 20.1 Fixed and Other Non - Current Assets 88.1 72.1 32.7 36.9 Current Liabilities 7.8 7.9 Non - Current Liabilities 47.5 27.4 Shareholders’ Equity 88.1 72.1 Note: Translated for convenience of the reader to U.S. dollars at the exchange rate of 1 Euro = 1.1734 USD, on September 30, 2025 and at the exchange rate of 1 Euro = 1.1145 USD, on September 30, 2024.

Positioned for Growth S U M M A R Y • Large Addressable Markets in Men’s and Women’s Health • Growing Install base of Leading Tier 1 Academic and Community Hospitals • Differentiated Non - Invasive Robotic HIFU Technology Solving Unmet Needs for Prostate Cancer, BPH and Endometriosis • Strong Clinical Evidence with Favorable Reimbursement in Place • Proven Management Team from Industry - Leading MedTech Companies 44

The Global Leader in Therapeutic Ultrasound 45

FAQ

What does EDAP TMS (EDAP) do in the medical device market?

EDAP TMS focuses on therapeutic ultrasound, led by its Focal One robotic HIFU platform used to treat prostate cancer, with expansion into benign prostatic hyperplasia (BPH) and deep infiltrating endometriosis.

How did EDAP TMS perform financially in the quarter ended September 30, 2025?

For the three months ended September 30, 2025, EDAP reported revenue of $16.1 million, up from $14.4 million, with gross margin improving to 43.0%. The company posted an operating loss of $5.7 million and a net loss of $5.8 million.

How fast is EDAP TMS’s HIFU business growing?

In the quarter ended September 30, 2025, HIFU revenue rose to $7.7 million from $4.9 million, while for the nine-month period HIFU revenue increased to $23.9 million from $16.3 million, indicating strong growth within the product mix.

Is EDAP TMS profitable based on the latest reported period?

No. EDAP reported an operating loss of $5.7 million and net loss of $5.8 million for the quarter, and a nine-month net loss of $19.8 million, although losses have narrowed slightly versus the prior year.

What is EDAP TMS’s cash position as of September 30, 2025?

As of September 30, 2025, EDAP held cash and cash equivalents of $12.4 million, compared with $28.4 million a year earlier, and reported shareholders’ equity of $27.4 million.

How widely is Focal One installed in the United States?

EDAP reports 76 Focal One systems installed in the U.S. as of September 30, 2025, across both academic and community hospitals, including a significant presence in top-ranked prostate cancer centers.

What markets beyond prostate cancer is EDAP targeting with Focal One?

EDAP is building clinical evidence to use Focal One in BPH-related symptoms and deep infiltrating rectal endometriosis, highlighting feasibility, phase I–III studies, and CE mark certification for certain endometriosis indications.